GlassScriptPhysician profile
Douglas S Kaplan
NPI 1518948918
$2,044.37
in general payments reported to CMS, 2019-2025
25 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $319 · 2021: $187 · 2022: $253 · 2023: $279 · 2024: $236 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $264.43 | 2019-2024 | Cequa |
| Alcon Vision LLC | $235.87 | 2019-2023 | Rocklatan |
| Aerie Pharmaceuticals, INC. | $215.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.77 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $126.63 | 2023 | Miebo, Vyzulta |
| Biotissue Holdings INC. | $120.00 | 2022 | |
| Allergan, INC. | $108.96 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $101.55 | 2024-2025 | Xdemvy |
| Abbvie INC. | $94.41 | 2023-2025 | |
| Glaukos Corporation | $76.71 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Idosetr |
| Harrow Eye, LLC | $69.88 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.61 | 2019-2020 | |
| The Cameron-Ehlen Group, INC. | $50.63 | 2020 | |
| Mallinckrodt Hospital Products INC. | $42.54 | 2024-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $42.07 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $38.26 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $29.18 | 2020 | |
| Quidel Corporation | $28.67 | 2020 | |
| Beaver-Visitec International, INC. | $24.70 | 2023 | |
| Horizon Therapeutics Plc | $23.93 | 2021 | |
| Thea Pharma INC. | $20.62 | 2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.39 | 2022 | |
| Akorn Operating Company LLC | $15.94 | 2021 | |
| Oyster Point Pharma, INC. | $13.50 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.